Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial

被引:46
作者
Dean, Olivia May [1 ,2 ,3 ]
Maes, Michael [4 ]
Ashton, Melanie [1 ]
Berk, Lesley [4 ]
Kanchanatawan, Buranee [5 ]
Sughondhabirom, Atapol [5 ]
Tangwongchai, Sookjareon [5 ]
Ng, Chee [6 ]
Dowling, Nathan [6 ]
Malhi, Gin S. [7 ,8 ]
Berk, Michael [1 ,2 ,3 ,9 ,10 ]
机构
[1] Deakin Univ, Sch Med, Innovat Mental & Phys Hlth & Clin Treatments Stra, Geelong, Vic 3220, Australia
[2] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia
[3] Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia
[4] Chulalongkorn Univ, Dept Psychiat, Bangkok, Thailand
[5] Deakin Univ, Sch Psychol, Ctr Mental Hlth & Wellbeing Res, Burwood, Australia
[6] Univ Melbourne, Melbourne Clin, Dept Psychiat, Richmond, Australia
[7] Univ Sydney, Discipline Psychiat, Sydney Med Sch, Sydney, NSW 2006, Australia
[8] CADE Clin, Dept Psychiat, St Leonards, NSW, Australia
[9] Orygen Youth Hlth Res Ctr, Parkville, Vic, Australia
[10] Univ Melbourne, Ctr Youth Mental Hlth, Parkville, Vic 3052, Australia
关键词
Minocycline; Depression; Clinical research protocol; Inflammation; Oxidative stress; OXIDATIVE STRESS; NITRIC-OXIDE; NEUROPROTECTION; NEUROTOXICITY; INFLAMMATION; EXPRESSION; CYTOKINES; RESPONSES; PATHWAYS; DAMAGE;
D O I
10.9758/cpn.2014.12.3.180
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
While current pharmacotherapies are efficacious, there remain a clear shortfall between symptom remission and functional recovery, With the explosion in our understanding of the biology of these disorders, the time is ripe for the investigation of novel therapies. Recently depression is conceptualized as an immune inflammatory and nitro oxidative stress related disorder. Minocycline is a tetracycline antibiotic that has anti inflammatory, pro oxidant, glutamatergic, neurotrophic and neuroprotective properties that make it a viable target to explore as a new therapy. This double blind, randomised, placebo controlled adjunctive trial will investigate the benefits of 200 mg/day of minocycline treatment, in addition to any usual treatment, as an adjunctive treatment for moderate severe major depressive disorder. Sixty adults are being randomised to 12 weeks of treatment (with a 4 week follow up post discontinuation), The primary outcome measure for the study is mean change on the Montgomery-Asberg Depression Rating Scale (MADRS), with secondary outcomes including the Social and Occupational Functioning Assessment Scale (SOFAS), Clinical Global Impressions (CGI), Hamilton Rating Scale for Anxiety (HAM A), Patient Global Impression (PGI), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and Range of Impaired Functioning Tool (LIFE RIFT). Biomarker analyses will also be conducted at baseline and week 12. The study has the potential to provide new treatment targets, both by showing efficacy with a new class of 'antidepressant' but also through the analysis of biomarkers that may further inform our understanding of the pathophysiology of unipolar depression.
引用
收藏
页码:180 / 188
页数:9
相关论文
共 43 条
[1]   Protective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity [J].
Ahuja, Manuj ;
Bishnoi, Mahendra ;
Chopra, Kanwaljit .
TOXICOLOGY, 2008, 244 (2-3) :111-122
[2]   Clinical relevance of the neurotrophins and their receptors [J].
Allen, SJ ;
Dawbarn, D .
CLINICAL SCIENCE, 2006, 110 (02) :175-191
[3]  
[Anonymous], 2001, The world health report-mental health: New understanding, new hope
[4]   Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline [J].
Arakawa, Shiho ;
Shirayama, Yukihiko ;
Fujita, Yuko ;
Ishima, Tamaki ;
Horio, Mao ;
Muneoka, Katsumasa ;
Iyo, Masaomi ;
Hashimoto, Kenji .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2012, 100 (03) :601-606
[5]   Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression [J].
Bech, P ;
Tanghoj, P ;
Cialdella, P ;
Andersen, HF ;
Pedersen, AG .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 (03) :283-290
[6]   Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors [J].
Berk, M. ;
Kapczinski, F. ;
Andreazza, A. C. ;
Dean, O. M. ;
Giorlando, F. ;
Maes, M. ;
Yuecel, M. ;
Gama, C. S. ;
Dodd, S. ;
Dean, B. ;
Magalhaes, P. V. S. ;
Amminger, P. ;
McGorry, P. ;
Malhi, G. S. .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2011, 35 (03) :804-817
[7]   Antioxidative enzyme activities and lipid peroxidation in major depression:: alterations by antidepressant treatments [J].
Bilici, M ;
Efe, H ;
Köroglu, MA ;
Uydu, HA ;
Bekaroglu, M ;
Deger, O .
JOURNAL OF AFFECTIVE DISORDERS, 2001, 64 (01) :43-51
[8]   The Role of BDNF and Its Receptors in Depression and Antidepressant Drug Action: Reactivation of Developmental Plasticity [J].
Castren, Eero ;
Rantamaki, Tomi .
DEVELOPMENTAL NEUROBIOLOGY, 2010, 70 (05) :289-297
[9]   Behavioral responses during the forced swim test are not affected by anti-inflammatory agents or acute illness induced by lipopolysaccharide [J].
Deak, T ;
Bellamy, C ;
D'Agostino, LG ;
Rosanoff, M ;
McElderry, NK ;
Bordner, KA .
BEHAVIOURAL BRAIN RESEARCH, 2005, 160 (01) :125-134
[10]   Minocycline Therapeutic Potential in Psychiatry [J].
Dean, Olivia M. ;
Data-Franco, Joao ;
Giorlando, Francesco ;
Berk, Michael .
CNS DRUGS, 2012, 26 (05) :391-401